Ashkon Software

   







 


KITE - Kite Pharma, Inc.

Kite Pharma, Inc. logo Kite Pharma, Inc. is a biopharmaceutical company that specializes in the development and commercialization of cancer immunotherapy products. The company focuses on developing chimeric antigen receptor (CAR) and T cell receptor (TCR) engineered cell therapies for the treatment of cancer. Its lead product candidate is axicabtagene ciloleucel, an autologous T-cell therapy, which is in Phase II clinical trials for the treatment of patients with refractory aggressive non-Hodgkin lymphoma.

Kite Pharma was founded in 2009 and is headquartered in Santa Monica, California. The company has a strong research and development team, with a focus on developing novel cell therapies for the treatment of cancer. The company's approach is based on the use of genetically engineered T cells, which are designed to target and kill cancer cells.

Kite Pharma has been recognized for its innovative approach to cancer immunotherapy and has received significant funding from the National Cancer Institute, the National Institutes of Health, and other organizations. The company has also entered into strategic partnerships with other companies in the biopharmaceutical industry to accelerate the development and commercialization of its product candidates.

Kite Pharma has a strong financial position, with a market capitalization of over $10 billion as of March 2023. The company has reported strong revenue growth in recent years, driven by the launch of its first product, Yescarta, which is approved for the treatment of relapsed or refractory large B-cell lymphoma. Kite Pharma was acquired by Gilead Sciences in 2017 for $11.9 billion, which has provided the company with additional resources to support its ongoing research and developme

 



 

 

 
Copyright © 2000-2024, Ashkon Software LLC
Privacy Policy | Refund Policy | Disclaimer